Literature DB >> 12026215

Clinical features of tuberous sclerosis cases.

Ayhan Söğüt1, Meral Ozmen, Serra Sencer, Mine Calişkan, Nur Aydinli, Türkan Ertuğrul, Gönül Peksayar.   

Abstract

Tuberous sclerosis (TS) is an autosomal dominant, multisystemic and neurocutaneous disease with high spontaneous mutation rate, and it mostly involves the skin, brain, kidneys, heart and the eyes. This study included 35 patients diagnosed with tuberous sclerosis and aged 6 months to 17 years, with a mean age of 6.5+/-4.8 years. The most frequently observed manifestations were those of the skin (97.1%) and of the central nervous system (seizures 94.2%, mental retardation 51.4%), followed by renal (32.2%), cardiac (25.8%) and ocular (22.5%) manifestations. Among cutaneous manifestations, hypomelanotic macules (94.3%), facial angiofibromas (40%), shagreen spots (20%), fibrous plaques on the forehead (5.7%) and ungula fibromas (5.7%) were observed. Tonic seizures (37.1%) and infantile spasms (21.2%) accounted for majority of seizures. Neurophysiological development was normal in 25.6% of cases, retarded in 51.4% and borderline in 23%. Thirty-four patients had typical pathological findings on magnetic resonance imaging (MRI). In conclusion, the earliest and most frequent complaint is seizure in cases with TS. Careful investigation for hypomelanotic macules and other skin manifestations typical for TS in cases presenting with convulsion makes early diagnosis possible and obviates unnecessary investigations.

Entities:  

Mesh:

Year:  2002        PMID: 12026215

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Autism and mental retardation with convulsion in tuberous sclerosis: a case report.

Authors:  Asok Kumar Datta; Syamali Mandal; Suvo Bhattacharya
Journal:  Cases J       Date:  2009-07-31

2.  Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.

Authors:  Mari Wataya-Kaneda; Mari Tanaka; Toshimitsu Hamasaki; Ichiro Katayama
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.